Medna Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 25-12-2024
- Paid Up Capital ₹ 0.10 M
as on 25-12-2024
- Company Age 3 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.50 M
as on 25-12-2024
- Revenue 152.01%
(FY 2023)
- Profit 106.24%
(FY 2023)
- Ebitda -72.51%
(FY 2023)
- Net Worth 3.33%
(FY 2023)
- Total Assets 33.80%
(FY 2023)
About Medna Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.50 M.
Rupali Singh and Mitali Singh serve as directors at the Company.
- CIN/LLPIN
U24230HR2021PTC092403
- Company No.
092403
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jan 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Yamuna Nagar, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Medna Biotech Private Limited offer?
Medna Biotech Private Limited offers a wide range of products and services, including Respiratory System Drugs, Anti Asthma Drug, Common Disease Medicines, Skin Lightening Drugs, Psoriasis Ointment, Pain Relief Drugs & Pharmaceuticals, Diclofenac, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Ointment.
Who are the key members and board of directors at Medna Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rupali Singh  | Director | 22-Jul-2022 | Current |
| Mitali Singh | Director | 17-Dec-2021 | Current |
Financial Performance of Medna Biotech.
Medna Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 152.01% increase. The company also saw a substantial improvement in profitability, with a 106.24% increase in profit. The company's net worth moved up by a moderate rise of 3.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medna Biotech?
Unlock access to Medna Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 29 Dec 2021 | ₹1.50 M | Open |
How Many Employees Work at Medna Biotech?
Medna Biotech has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medna Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medna Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
